Skip to main content

Table 2 Major ongoing clinical trials of elotuzumab

From: Elotuzumab for the treatment of multiple myeloma

NCT number Title Ph N Recruitment
NCT01335399 (ELOQUENT-1) Phase III study of lenalidomide and dexamethasone with or without elotuzumab to treat newly diagnosed, previously untreated multiple myeloma 3 750 Active, not recruiting
NCT02272803 Phase II study of lenalidomide/dexamethasone with or without elotuzumab for newly diagnosed MM patients in Japan 2 80 Recruiting
NCT01241292 Japanese study of BMS-901608 (Elotuzumab) in combination with lenalidomide and low dose dexamethasone 1 7 Active, not recruiting
NCT02159365 Study of safety of elotuzumab administered over approximately 60 min in combination with lenalidomide and dexamethasone for newly diagnosed or relapsed/refractory multiple myeloma patients 2 76 Active, not recruiting
NCT01393964 Study of elotuzumab in combination with lenalidomide and dexamethasone in subjects with multiple myeloma and various levels of renal function 1 35 Active, not recruiting
NCT02279394 Trial of combination of elotuzumab and lenalidomide +/− dexamethasone in high-risk smoldering multiple myeloma 2 82 Recruiting
NCT02420860 Study of elotuzumab with lenalidomide as maintenance after autologous stem cell transplant (ASCT) 2 100 Recruiting
NCT02655458 Elotuzumab in autologous stem cell transplantation (ASCT) and lenalidomide maintenance for multiple myeloma 1 15 Recruiting
NCT02612779 A study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd) in patients with multiple myeloma relapsed or refractory to prior treatment with lenalidomide 2 60 Recruiting
NCT02654132 Trial of pomalidomide and low-dose dexamethasone with or without elotuzumab to treat refractory and relapsed and refractory multiple myeloma (ELOQUENT-3) 2 121 Recruiting
NCT01668719 (S1211) Bortezomib, dexamethasone, and lenalidomide with or without elotuzumab in treating patients with newly diagnosed high-risk multiple myeloma 1/2 122 Recruiting
NCT02375555 Study of bortezomib, lenalidomide, dexamethasone & elotuzumab in newly diagnosed MM 2 40 Recruiting
NCT02495922 (GMMG HD6) A phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma 3 516 Recruiting
NCT02718833 A study of elotuzumab with pomalidomide, bortezomib, and dexamethasone in relapsed multiple myeloma 2 46 Recruiting
NCT02726581 Study of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in multiple myeloma 3 406 Recruiting
NCT02252263 A phase I open label study of the safety and tolerability of elotuzumab (BMS-901608) administered in combination with either lirilumab (BMS-986015) or urelumab (BMS-663513) in subjects with multiple myeloma 1 136 Active, not recruiting
  1. Ph phase; N number